BinaxNOW COVID-19 AgCARD By Abbott - (40 Count) CLIA Waived 195-000 - 1 Case (640 Tests)
BinaxNOW COVID-19 AgCARD By Abbott - (40 Count) CLIA Waived 195-000 - 1 Case (640 Tests)
BinaxNOW COVID-19 AgCARD By Abbott - (40 Count) CLIA Waived 195-000 - 1 Case (640 Tests)
BinaxNOW COVID-19 AgCARD By Abbott - (40 Count) CLIA Waived 195-000 - 1 Case (640 Tests)
BinaxNOW COVID-19 AgCARD By Abbott - (40 Count) CLIA Waived 195-000 - 1 Case (640 Tests)
BinaxNOW COVID-19 AgCARD By Abbott - (40 Count) CLIA Waived 195-000 - 1 Case (640 Tests)
BinaxNOW COVID-19 AgCARD By Abbott - (40 Count) CLIA Waived 195-000 - 1 Case (640 Tests)
BinaxNOW COVID-19 AgCARD By Abbott - (40 Count) CLIA Waived 195-000 - 1 Case (640 Tests)
BinaxNOW COVID-19 AgCARD By Abbott - (40 Count) CLIA Waived 195-000 - 1 Case (640 Tests)

BinaxNOW COVID-19 AgCARD By Abbott - (40 Count) CLIA Waived 195-000 - 1 Case (640 Tests)

BinaxAG-Case

Special Price $5,999.99

InStock

Product Details

UPC: 0081187701140

Brand: BinaxNOW

MPN: 195000

Manufacturer: Abbott

Weight: 17.00 lbs

Description Of Our BinaxNOW™ COVID-19 Ag Card

For Rapid Detection of SARS-CoV-2 | FDA EUA | IVD Use | RX Only

Performance Data Submitted To The FDA By Abbott:

  • Sensitivity: 97.1%
  • Specificity: 98.5%

The BinaxNOW™ COVID-19 Ag Card is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection.

Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status.

Negative results should be treated as presumptive, do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions.

The BinaxNOW™ COVID-19 Ag Card is intended for use by medical professionals or trained operators who are proficient in performing rapid lateral flow tests. BinaxNOW™ COVID-19 Ag Card is only for use under the Food and Drug Administration’s EUA.


Abbott BinaxNow AGCard 40 Pack 195-000 Box Contents:

The contents below are per a box (40 Tests):

Test Cards (40): A cardboard, book-shaped hinged test card containing the test strip 

Extraction Reagent (1): Bottle containing 7.5 mL of extraction reagent 

Nasal Swabs (40): Sterile swabs for use with BinaxNOW COVID-19 Ag Card test 

Positive Control Swab (1) : Non-infectious recombinant SARS-CoV-2 nucleocapsid antigen dried onto a swab 

Negative Control Swab: The use of a sterile patient swab ensures appropriate negative results are obtained 

Product Insert (1) 

Procedure Card (1)

    Customer Reviews



    Recent Reviews

    No Reviews yet